Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

BACKGROUND: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Hematol Oncol
Hauptverfasser: Cortes, Jorge E., Heidel, Florian H., Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Candoni, Anna, Leber, Brian, Sekeres, Mikkael A., Pollyea, Daniel A., Ferdinand, Roxanne, Ma, Weidong Wendy, O’Brien, Thomas, O’Connell, Ashleigh, Chan, Geoffrey, Heuser, Michael
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2020
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362563/
https://ncbi.nlm.nih.gov/pubmed/32664995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00929-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge